BMO Capital Downgrades Exelixis to Market Perform, Raises Price Target to $40
EXELDecember 20, 2024
Read more →Reddit, Roblox And Garmin Are Among Top 10 Large Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio?
EXELThe top 10 performers last week were Reddit, Paycom, Mobileye, Exelixis, Garmin, Roblox, Twilio, Snap, Waters, and Atlassian. Many analysts raised price forecasts.
November 3, 2024
Read more →Exelixis Settles With Cipla To Resolve Two Patent Litigation; Grants Cipla License To Market Generic Versions Of CABOMETYX On Jan 1, 2031 If Approved By FDA And Subject To Conditions; Parties Terminate All Hatch-Waxman Litigation Regarding CABOMETYX
EXELMay 20, 2024
Read more →Exelixis' XL092/ Atezolizumab Shows Encouraging Efficacy, Safety In Heavily Pretreated Cancer Patients
EXELSeptember 12, 2022
Read more →Exelixis Announces Detailed Results From Late-Stage Cabometyx Combo Trial In Kidney Cancer
EXELSeptember 8, 2022
Read more →Exelixis' Partner Ipsen Receives European Commission Approval For CABOMETYX For Patients With Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
EXELMay 3, 2022
Read more →Ipsen - Exelixis' Cabometyx Scores European Approval As Second-Line Treatment For Thyroid Cancer
EXELMay 3, 2022
Read more →